Article

Quantifying factors for the success of stratified medicine.

Massachusetts Institute of Technology, Sloan School of Management and Center for Biomedical Innovation, 100 Main Street, Cambridge, Massachusetts 02139, USA.
dressNature Reviews Drug Discovery (Impact Factor: 37.23). 11/2011; 10(11):817-33. DOI: 10.1038/nrd3557
Source: PubMed

ABSTRACT Co-developing a drug with a diagnostic to create a stratified medicine - a therapy that is targeted to a specific patient population on the basis of a clinical characteristic such as a biomarker that predicts treatment response - presents challenges for product developers, regulators, payers and physicians. With the aim of developing a shared framework and tools for addressing these challenges, here we present an analysis using data from case studies in oncology and Alzheimer's disease, coupled with integrated computational modelling of clinical outcomes and developer economic value, to quantify the effects of decisions related to key issues such as the design of clinical trials. This illustrates how such analyses can aid the coordination of diagnostic and drug development, and the selection of optimal development and commercialization strategies. It also illustrates the impact of the interplay of these factors on the economic feasibility of stratified medicine, which has important implications for public policy makers.

Download full-text

Full-text

Available from: Aiden A Flynn, Jan 22, 2015
2 Followers
 · 
130 Views
  • Source
    • "For example, applying the systems approach could help identify the mode of action and potential toxicity of compounds under development, which would allow companies to terminate unfavorable development projects early. The systems approach could also help to identify human subpopulations who may not respond to certain therapeutics, which would bring us closer to the goal of achieving personalized medicine (Trusheim et al. 2011). Merck Research Laboratory (MRL) was among the first research institutes to perform integrated analysis of large scale genomics data sets, and to apply the results toward practical drug development (Dai et al. 2005; Schadt et al. 2009; van't Veer et al. 2002, 2003; van de Vijver et al. 2002). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The pharmaceutical industry is spending increasingly large amounts of money on the discovery and development of novel medicines, but this investment is not adequately paying off in an increased rate of newly approved drugs by the FDA. The post-genomic era has provided a wealth of novel approaches for generating large, high-dimensional genetic and transcriptomic data sets from large cohorts of preclinical species as well as normal and diseased individuals. This systems biology approach to understanding disease-related biology is revolutionizing our understanding of the cellular pathways and gene networks underlying the onset of disease, and the mechanisms of pharmacological treatments that ameliorate disease phenotypes. In this article, we review a number of approaches being used by pharmaceutical and biotechnology companies, e.g., high-throughput DNA genotyping, sequencing, and genome-wide gene expression profiling, to enable drug discovery and development through the identification of new drug targets and biomarkers of disease progression, drug pharmacodynamics, and predictive markers for selecting the patients most likely to respond to therapy.
    Current topics in microbiology and immunology 08/2012; 363. DOI:10.1007/82_2012_252
  • Source
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Most health care recommendations in the United States have come from trials designed to measure efficacy of medical interventions, with randomized controlled trials considered the gold standard for evidence-based medicine. Comparative effectiveness research has become an essential component of research to help define the benefits, risks, and effectiveness of different interventions for a particular illness. Comparative effectiveness research is informally defined as an assessment of all available options for a specific medical condition, with intent to estimate effectiveness in specific subpopulations. In this article, we contrast efficacy-based healthcare research and recommendations in the United States, under the model of evidence-based medicine, to the contemporary paradigm of comparative effectiveness research. We review the recent emphasis by the federal government on comparative effectiveness research. Finally, we review the limitations of effectiveness and efficiency.
Show more